- Home
- EDF vs IKT Comparison
EDF vs IKT Comparison
Compare EDF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- IKT
- Stock Information
- Founded
- EDF 2010
- IKT 2008
- Country
- EDF United States
- IKT United States
- Employees
- EDF N/A
- IKT N/A
- Industry
- EDF Investment Managers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- IKT Health Care
- Exchange
- EDF Nasdaq
- IKT Nasdaq
- Market Cap
- EDF 148.8M
- IKT 167.2M
- IPO Year
- EDF N/A
- IKT 2020
- Fundamental
- Price
- EDF $4.68
- IKT $1.90
- Analyst Decision
- EDF
- IKT Buy
- Analyst Count
- EDF 0
- IKT 2
- Target Price
- EDF N/A
- IKT $8.00
- AVG Volume (30 Days)
- EDF 160.6K
- IKT 147.0K
- Earning Date
- EDF 01-01-0001
- IKT 05-14-2025
- Dividend Yield
- EDF 13.14%
- IKT N/A
- EPS Growth
- EDF N/A
- IKT N/A
- EPS
- EDF N/A
- IKT N/A
- Revenue
- EDF N/A
- IKT N/A
- Revenue This Year
- EDF N/A
- IKT N/A
- Revenue Next Year
- EDF N/A
- IKT N/A
- P/E Ratio
- EDF N/A
- IKT N/A
- Revenue Growth
- EDF N/A
- IKT N/A
- 52 Week Low
- EDF $3.51
- IKT $1.12
- 52 Week High
- EDF $5.50
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- EDF 46.64
- IKT 42.84
- Support Level
- EDF $4.22
- IKT $1.58
- Resistance Level
- EDF $5.09
- IKT $2.22
- Average True Range (ATR)
- EDF 0.15
- IKT 0.22
- MACD
- EDF -0.00
- IKT 0.00
- Stochastic Oscillator
- EDF 56.84
- IKT 45.57
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.